CPA
ANIK icon

Capital Performance Advisors’s Anika Therapeutics ANIK Stock Holding History

Capital Performance Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$1.24K – 309
2024
Q3 		$1.24K Buy
+50
New +$1.3K ﹤0.01% 1805

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Capital Performance Advisors's ANIK Position: Q4 2024 in Review

Capital Performance Advisors sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 50 shares — an estimated $1.24K sold.

Capital Performance Advisors first reported a position in ANIK in Q3 2024 and held it in 1 quarter. The position peaked at $1.24K in Q3 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Capital Performance Advisors reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 50 Anika Therapeutics shares in Q4 2024, an estimated $1.24K.
  • Capital Performance Advisors first reported a position in Anika Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Anika Therapeutics position peaked at $1.24K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.